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Abstract
Background:  We sought to determine whether a multi-modal intervention, which included
mailing a patient reminder with a colon cancer decision aid to patients and system changes allowing
direct access to scheduling screening tests through standing orders, would be an effective and
efficient means of promoting colon cancer screening in primary care practice.
Methods: We conducted a controlled trial comparing the proportion of intervention patients who
received colon cancer screening with wait list controls at one practice site. The intervention was
a mailed package that included a letter from their primary care physician, a colon cancer screening
decision aid, and instructions for obtaining each screening test without an office visit so that
patients could access screening tests directly. Major outcomes were screening test completion and
cost per additional patient screened.
Results: In the intervention group, 15% (20/137) were screened versus 4% (4/100) in the control
group (difference 11%; (95%; CI 3%;18% p = 0.01). The cost per additional patient screened was
estimated to be $94.
Conclusion: A multi-modal intervention, which included mailing a patient reminder with a colon
cancer decision aid to patients and system changes allowing patients direct access to schedule
screening tests, increased colon cancer screening test completion in a subset of patients within a
single academic practice. Although the uptake of the decision aid was low, the cost was also
modest, suggesting that this method could be a viable approach to colon cancer screening.
Background
Colon cancer is the second leading cause of cancer-related
deaths in the United States, and the third most commonly
diagnosed cancer, with over 149,000 new diagnoses and
55,000 deaths expected in 2006 [1]. Colon cancer screen-
ing is effective in decreasing colon cancer incidence and
mortality [2-4], and there are several recommended
screening tests available to patients [5]. Despite its effec-
tiveness, colon cancer screening is underutilized in the
United States. Recent data on self-reported screening sta-
tus from the Behavioral Risk Factor Surveillance System
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survey shows that only 57% of people in the United States
are up to date with recommended screening [6].
Barriers at multiple levels of the healthcare system (physi-
cian, patient, and system levels) contribute to the underu-
tilization of colon cancer screening, and targeting these
barriers increases colon cancer screening [7,8]. One
important barrier is lack of awareness about when screen-
ing is due. This barrier has been effectively targeted with
system changes such as reminders to physicians or
patients [9,10]. Another important patient barrier to
screening is not understanding the importance of screen-
ing and difficulty choosing among multiple options. A
colon cancer screening decision aid for patients has been
shown to promote screening by educating and facilitating
choice between different testing options [11]. However,
implementation of decision aids in clinical practice can be
difficult due to space and time constraints and may not
reach all patients who are eligible; furthermore, patients
who receive decision aids while in physicians' offices and
are ready to be screened may still not have their preferred
screening tests ordered by their physician [12].
Therefore, providing patients with decision aids outside of
clinical practice, including information on how to obtain
screening tests without an additional office visit, could
produce a greater effect and be more efficient than provid-
ing decision aids in the practice setting. In this study, we
sought to determine whether a multi-modal intervention,
which included mailing a patient reminder with a colon
cancer screening decision aid to patients and system
changes allowing direct access to screening test schedul-
ing, would be an effective and efficient means of promot-
ing colon cancer screening in primary care practice.
Primary outcomes were completion of colon cancer
screening tests and cost of each additional patient
screened.
Methods
We conducted a controlled trial assessing the main out-
come of colon cancer screening test completion for inter-
vention patients and a waitlist control group at one
practice site. Colon cancer screening receipt was deter-
mined by chart review five months after the intervention
was mailed. The control group received the intervention
materials after the study outcome data had been collected.
Setting
We conducted this trial at the University of North Caro-
lina Ambulatory Care Center in the General Internal Med-
icine practice (ACC-GIM). This is an academic practice
that cares for over 5,000 adults aged 50 and older. The
ACC GIM includes 15 attending physicians and 46 resi-
dent physicians.
Patient Ascertainment
To track the status of colon cancer screening in patients at
the ACC-GIM, we developed a tracking system in Micro-
soft Access. The database collects colon cancer screening
test completion records from billing data obtained from
the University of North Carolina (UNC) Healthcare Sys-
tem for flexible sigmoidoscopy and colonoscopy, as well
as from lab results at ACC-GIM for fecal occult blood tests.
Testing outside of the UNC System is uncommon but not
captured in the billing database. Consequently, some
patients who have no record of being up to date with
screening may have, in fact, completed outside screening.
For this study, we used this database to identify patients
ages 50 to 75 who did not have documented colon cancer
screening in our database, i.e., not having a colonoscopy
in the last 10 years, flexible sigmoidoscopy in the last five
years, or fecal occult blood testing in the last 11 months.
We first identified 5,381 adults in this age range who were
active patients, having been seen at the ACC-GIM at least
once in the previous two years. We then identified 2,788
of the 5,381 (52%) who did not have documentation of
being up to date with colon cancer screening. For this
pilot study, we chose patients of attending physicians
because we were more confident of the correct association
in our database between patient and primary care physi-
cian than with patients of resident physicians. We identi-
fied 1,150 attending physician patients that met our
eligibility criteria. Each attending physician reviewed their
respective patient list and excluded patients who they
deemed too ill to benefit from screening.
The remaining patients (n = 907) not excluded by the
attending physicians were divided in half alphabetically
by last name to form intervention and control/waitlist
groups. A through L served as the pool for the intervention
group and M through Z for the control/waitlist groups.
From this pool, we selected a sub-sample to evaluate the
intervention in depth prior to the full trial. We chose the
first 137 patients of attending physicians listed alphabeti-
cally in the intervention pool for the intervention group
and the first 100 patients of attending physicians in the
control group.
Description of Intervention
The intervention consisted of a mailed package containing
the following materials:
• A letter, signed by the patient's physician, reminding the
patient that they were due for screening and encouraging
them to get screened.
￿ A survey entitled 'Colon Cancer Health Summary' to be
completed prior to watching the video to determine
screening history and personal or family history of polyps,Implementation Science 2008, 3:32 http://www.implementationscience.com/content/3/1/32
Page 3 of 8
(page number not for citation purposes)
colon cancer, or inflammatory bowel disease; from this
information we could determine whether the patient
believed that they were eligible for routine screening.
￿ A decision aid, 'Colon Cancer Screening: Deciding
What's Right for You', in VHS and DVD format.
￿ A survey to be completed after watching the decision
aid, measuring secondary outcomes of including interest
and acceptability of the intervention.
￿ Information encouraging return of all materials, partic-
ularly the Colon Cancer Health Summary, regardless of
screening status.
￿ Instructions and postage for returning the package.
The decision aid used in this study was created by the
Foundation for Informed Medical Decision Making in
conjunction with one of the authors (MP). The program is
approximately 35 minutes long. A moderator leads a dis-
cussion about colon cancer and colon cancer screening.
The first section describes colon cancer and the risk of get-
ting colon cancer for those at average risk. The next sec-
tions of the decision aid video describe the different types
of colon cancer screening tests, including: fecal occult
blood test, sigmoidoscopy, a combination of fecal occult
blood test and sigmoidoscopy, and colonoscopy. Each
test was described in terms of how the test is completed,
how often it needs to be completed, the amount of time
needed to complete the test, effectiveness in finding pol-
yps and cancer, convenience, discomfort, and risks associ-
ated with the test. Patient testimonials are interspersed for
each testing option where patients describe their experi-
ences with specific tests.
Detailed instructions on how to access the screening test
of choice were included in the intervention package. For
fecal occult blood testing, standing orders were imple-
mented in the practice. A nurse facilitator was available by
phone so patients could request fecal occult blood cards
be sent to them and returned to the practice in a prepaid
envelop. For flexible-sigmoidoscopy and colonoscopy
patients were provided the number to the gastroenterol-
ogy suite affiliated with UNC hospital. Schedulers in the
gastroenterology suite were instructed to schedule
patients who requested either test.
One month after the initial mailing, we sent a reminder
letter to those intervention patients who had not returned
materials. This reminder included a letter from the
patient's physician stating again that they were due for
screening, encouraging them to get screened, and remind-
ing them to return the intervention materials.
Primary Outcomes
Colon cancer screening test completion
Colon cancer screening test completion was determined
by medical record review five months after mailing the
intervention. The review was completed by two independ-
ent reviewers, one of whom was blinded to intervention
status. Inter-rater reliability was assessed using the kappa
statistic, and disagreements were resolved afterward by
group discussion. The kappa statistic was 0.90 (95% CI
0.83, 0.96), indicating excellent agreement. The analysis
was an intention to treat analysis. We included all patients
in the intervention group even if they reported being at
high risk or previously screened because we did not have
similar information for the control group. This analysis
allowed for the most conservative estimate of the inter-
vention effect.
Cost
The other major outcome of interest was cost per addi-
tional patient screened. We calculated approximate cost
per additional patient screened by estimating costs of
postage, mailing materials, VHS and DVD duplication
costs, and staff time spent sending the mailings (Table 1).
We did not include staff time devoted to making the
phone calls as this was considered part of the evaluation
and not the intervention itself.
Secondary Outcomes
For the intervention group, we attempted to determine
several secondary outcomes, either through in the post-
video questionnaire for patients who responded to the
Table 1: Estimations for the cost per additional patient screened
Item Cost Quantity Cost
Mail out postage $1.84 137 mailed packages $252.08
Mail back postage $5.00 57 returned by patients $285.00
Video/DVD duplication costs $5.00 137 $685.00
Materials (Boxes and packaging $1.00 137 $137.00
Staff time $17.00/hour 9 hours staff time $153.00
Total Cost $1,512.08
Cost per additional patient screened Difference in patients screened between intervention and control = 
16 patients
$1,512.08/16 $94.51Implementation Science 2008, 3:32 http://www.implementationscience.com/content/3/1/32
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intervention by completing the written survey or via tele-
phone interview for those that did not respond to the writ-
ten questionnaire. Two months after the initial mailings,
we attempted to contact via telephone those who either
had not responded to the mailing (non-respondent) or
those who had sent the materials back without a written
response (non-participant). We made five call attempts to
each non-respondent or non-participant. The intent of the
calls was not to try to encourage screening, but to deter-
mine several secondary outcomes.
In both the post-video questionnaire and the telephone
interview we asked questions about the acceptability of
the intervention to those who were eligible for screening
by asking if they liked receiving the decision aid in the
mail. We also measured interest in screening and asked if
they had attempted to schedule a screening test since
receiving the intervention.
Results
The intervention and control groups were similar in
regards to age, sex, and race (Table 2).
Response to mailings
Of the 137 intervention patients, 57 people (42%)
responded; 31 completed the materials, and 26 people
did not complete any of the materials (non-participants).
Among the 31 patients who completed materials, 12
reported that they were eligible for the decision aid, and
19 reported being up to date with screening or at high risk
(Figure 1). Nine of the mailings were returned as undeliv-
erable due to incorrect addresses (6%), and 71 patients
(52%) did not respond.
Primary Outcomes
Screening test completion
In the intervention group 15% of patients (20/137) were
screened versus 4% of patients (4/100) in the control
group (difference 11%;95% CI 3%, 18% P = 0.01
Cost per additional patient screened
The total cost of the intervention was calculated to be
$1,512.08. The majority of the cost was attributed to the
video costs ($685). The cost per additional patient
screened was estimated to be $94 (Table 1).
Secondary Outcomes
Responses to mailed survey
All eligible respondents (n = 12) reported that they were
interested in screening; four had attempted to schedule a
screening test since receiving the intervention materials
and one reported difficulty in doing so. Eleven of the 12
respondents reported that they liked receiving the mailing
and had watched the video. Five of these 12 obtained a
screening test, four of whom had watched the video.
Responses to telephone interviews
We attempted to call both the 71 non-respondents and
the 26 non-participants in the intervention group to deter-
mine how our program was received and their self-
reported screening status (Figure 2). We were able to reach
and interview 55 of these 97 people (57%). We found that
21 were either up to date with screening or at high risk. Of
the remaining 30 people, 23 remembered receiving the
package. Among these 23 patients, 14 reported that they
had looked at the information, and six reported that they
had watched the video. When asked about screening, 11
patients reported that they were interested in undergoing
screening, and eight had tried to schedule a screening test.
From the medical record review we found that three had
obtained a screening test.
We asked those who had not watched the video why they
had not watched it: 10 patients reported that they had not
had time, two stated they did not have insurance so it was
not worth it to them to watch the video, two reported that
they were too scared of cancer to watch the video, one
reported that they did not have either a DVD or VHS
player, one had left the practice, and one did not provide
an answer. We asked 15 of the 23 patients whether they
liked receiving the decision aid; 12 liked receiving the
package and three reported that they did not.
Conclusion
We found that a multi-modal intervention, which
included mailing a patient reminder with a colon cancer
decision aid to patients of attending physicians and sys-
tem changes allowing patients direct access to schedule
screening tests, increased cancer screening test completion
by 11% (95%; CI 3%;18% p = 0.01) when compared to a
control group. We estimated the cost of the intervention
to be $94 per additional patient screened. The response to
the mailings was modest (42%), and about half who sent
a mailed response did not complete the written materials.
Our multi-modal intervention included a reminder letter
from their physician, a decision aid to educate and facili-
tate choice, and system changes to decrease barriers to
colon cancer screening test ordering. In a recent review
Stone et al. identified several studies that combined inter-
ventions in clinical practices to target colon cancer screen-
Table 2: Patient characteristics in intervention and control 
group
Intervention Control
N 137 100
Mean age 62 62
% Female 60 61
% White 60 62
% Black 30 28Implementation Science 2008, 3:32 http://www.implementationscience.com/content/3/1/32
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ing barriers at multiple levels [7]. However, none included
a decision aid as a part of the intervention. We identified
a randomized controlled trial performed by Zapka and
colleagues that mailed a colon cancer screening educa-
tional video to 450 primary care patients before their
scheduled appointment for a physical exam. Their study
found no significant difference in screening rates between
the intervention and control groups [13]. A potential rea-
son for the discrepancy in findings with our study could
be the intent of the video. The video used in our study was
aimed at facilitating choice between screening options,
whereas the video used in the Zapka et al. study was
focused on increasing screening by flexible sigmoidos-
copy. Additionally, our study provided direct access to
screening tests, while the Zapka and colleagues' study
encouraged discussion with providers and depended on
the practice to arrange the screening appointment. Our
previous work has shown that screening tests are often not
ordered, despite patient interest [12].
Recent studies have used a similar mass mailing to
patients to attempt to increase colon cancer screening
Response to mailing Figure 1
Response to mailing.
137 packages 
sent to patients
17
up to date with 
screening
9 (6%) 
returned to 
sender
26
patients returned 
materials without 
written response
19
ineligible
12
eligible
57 (42%) 
sent materials 
back
 71 (52%) 
did not return 
materials
2 higher risk
11 did watch 
decision aid
1
did not watch 
decision aidImplementation Science 2008, 3:32 http://www.implementationscience.com/content/3/1/32
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Phone call response Figure 2
Phone call response.
Attempted to 
contact 97 patients
35 (36%)
unable to be 
contacted
55 (57%) 
completed phone 
interview
7 (7%)
Refused phone 
interview
21
ineligible
4 incomplete 
surveys
30 completed 
survey
7 did not 
remember 
receiving package
23 remembered 
receiving package
14 did look at 
materials
9 did not look at 
materials
7 did not watch 
decision aid
6 watched 
decision aid
1 refused to 
answer question
71 patients 
did not 
return 
materials
26 patients 
returned 
materials 
without 
written 
responseImplementation Science 2008, 3:32 http://www.implementationscience.com/content/3/1/32
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rates with mixed results A study using self-reported screen-
ing completion as an outcome showed an increase in
colon cancer screening of 23% over one year when fecal
occult blood test cards and reminders were sent directly to
patients [14]. Using claims data instead of self-reporting,
Walsh and colleagues found no significant increase in
colon cancer screening rates for colonoscopy and fecal
occult blood tests after mailing patient educational mate-
rials and a letter encouraging screening; however, a small
(3%) increase in flexible sigmoidoscopy was observed
[15]. The 11% increase we found in screening rates could
be attributable to the decision aid that differed from the
educational materials sent by Walsh and colleagues, the
system changes we implemented, or a combination of
both.
Evaluating the costs of cancer screening programs is
important in deciding which programs are most effective
and efficient at promoting the targeted screening activity
[16]. Most assessments of screening program costs have
been conducted for breast cancer screening programs
directed to patients [17]. The effectiveness and efficiency
of mammography screening programs varies widely
depending on the baseline screening rates, the target pop-
ulation, the intensity of the intervention, and the method
for calculating costs. A low-intensity intervention similar
to our study that included a tailored letter and telephone
call to patients in a large HMO increased screening rates
by 20%. This intervention had a relatively high estimated
cost of additional patient screened of $818 [18]. Others
have estimated costs for comparable programs to be much
lower. Fishman et al. found that a telephone reminder
increased screening by 16%, with an estimated cost of $92
for previously adherent women and $100 for those previ-
ously non-adherent [19]. Saywell targeted non-adherent
women at a large HMO using telephone counseling and a
physician reminder letter, which was shown to increase
screening by 17% at an estimated a cost of $14 per addi-
tional patient screened [20]. Our estimated costs of $95
per additional patient screened compares favorably with
the breast cancer screening programs because colon can-
cer screening may be less acceptable and is complicated by
multiple testing options.
We were able to find only one other study that estimated
the cost per additional patient screened for colon cancer
screening. This study found comparable results to ours,
but was aimed specifically at physicians. The intervention
provided VA physicians with quarterly feedback on
screening rates of their patients. This intervention
increased colon cancer screening rates by 9%, with an
associated cost per additional patient screened of $196
[17].
Our study has several important limitations. First, our
sample size was small, making it possible that we found a
difference in screening rates by chance. The relatively tight
confidence intervals, however, suggest that this is
unlikely. Second, the study included only one academic
practice and a sub-sample of attending physicians'
patients within the practice, limiting the generalizability
of our findings. Third, the study was non-randomized,
which could introduce bias if there were unmeasured dif-
ferences between the intervention and control group
patients. Because we had a limited number of patient
characteristics available in our database we are not able to
exclude differences between the groups as a possible cause
for our findings. Although age, gender, and race were sim-
ilar between the groups, insurance status was not available
and could bias the control group to no screening if there
were fewer insured patients in the control group.
Although we found a difference in screening rates between
intervention and control groups, we were unable to iden-
tify which part of the intervention was responsible for the
difference in screening. Finally, our response rate to the
initial mailings and calls was modest, despite five calls per
patient. The views of the patients who refused or who we
were unable to reach may differ significantly from those
who we were able to interview.
A multi-modal intervention, which included mailing a
patient reminder with a colon cancer decision aid to
patients and system changes allowing patients direct
access to schedule screening tests, was effective in increas-
ing cancer screening test completion in a subset of
patients within a single academic practice. Although the
uptake of the decision aid was low, the cost was also mod-
est, suggesting that this method could be a viable cancer
screening program.
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